Join our daily newsletter At The Bell to receive exclusive market insights
- Race Oncology (RAC) secures another US patent for its cancer drug Zantrene
- This is the fifth patent granted for the drug in the United States
- Zantrene has shown it can kill melanoma cancer cells that overproduce the fat mass and obesity associated protein, FTO
- Race is up 0.94 per cent and is trading at $3.22 per share at 10:51 am AEDT
Race Oncology (RAC) has been issued a US patent for its cancer drug Zantrene.
The patent was issued by the United States Patent and Trademarks Office and is the fifth patent granted for Zantrene in the US.
Zantrene has shown it can kill melanoma cancer cells that overproduce the fat mass and obesity associated protein, FTO.
Currently, a collaborative preclinical melanoma research program is underway with the University of Newcastle. The program is exploring the use of Zantrene as a potential treatment for melanoma using cellular and mouse models.
CEO and Managing Director Phillip Lynch is pleased with the new patent.
“This latest US patent provides Race with additional protection around the use, formulation and compositions of Zantrene (and related chemical structures) that improve the therapeutic benefit of Zantrene,” he said.
The patent further expands Race’s intellectual property portfolio in the therapeutic utility of Zantrene.
Race was up 0.94 per cent and was trading at $3.22 per share at 10:51 am AEDT.
